Moderate

CKD progression — RAAS inhibition and SGLT2 nephroprotection

nephroprotection · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Evidence-based strategy to slow CKD progression using maximally tolerated ACE inhibitor/ARB plus an SGLT2 inhibitor in proteinuric or diabetic CKD, with BP, glycaemic and lifestyle optimisation. SGLT2 inhibitors reduce progression and cardiovascular events across diabetic and non-diabetic CKD.

Red flags

  • Creatinine rise >30% or hyperkalaemia >6.0 mmol/L after RAAS blockade
  • Rapidly declining eGFR (>5 mL/min/year) despite therapy
  • Euglycaemic DKA on SGLT2 inhibitor
  • New heavy proteinuria or active urinary sediment (glomerulonephritis)
  • Features of renovascular disease (flash pulmonary oedema, bilateral stenosis)

Assessment

Differential diagnosis

  • Diabetic kidney disease
  • Hypertensive nephrosclerosis
  • Chronic glomerulonephritis (IgA, FSGS)
  • Reflux/obstructive nephropathy
  • Polycystic kidney disease (not SGLT2-driven)
  • Superimposed AKI accelerating decline

Investigations

  • eGFR trend and urine ACR (albumin:creatinine ratio)
  • U&E, potassium and bicarbonate
  • HbA1c and lipid profile
  • Blood pressure (home/ambulatory)
  • Urinalysis for haematuria/active sediment
  • Renal ultrasound if obstruction or structural cause suspected

Management

  • Confirm CKD, quantify albuminuria with ACR and establish eGFR slope over time
  • Identify and treat reversible accelerants (uncontrolled BP, nephrotoxins/NSAIDs, obstruction, poor glycaemic control)
  • Start and uptitrate an ACE inhibitor or ARB to the maximum tolerated dose in CKD with ACR >=3 mg/mmol or hypertension
  • Check U&E 1-2 weeks after starting/uptitrating RAAS blockade; tolerate up to 25-30% creatinine rise and potassium up to 5.5 mmol/L
  • Add an SGLT2 inhibitor (dapagliflozin/empagliflozin) in CKD with ACR >=22 mg/mmol or diabetic kidney disease, down to eGFR ~20 mL/min/1.73m2
  • Counsel about an expected small initial eGFR dip (<10%) after SGLT2 start that then stabilises — do not stop for this
  • Give sick-day guidance to pause SGLT2 inhibitor during acute illness/dehydration (ketoacidosis risk)
  • Optimise blood pressure to target <130/80 (individualised) using the lowest effective additional agents
  • In residual albuminuria/diabetic CKD consider adding finerenone where potassium and eGFR permit
  • Reinforce lifestyle: smoking cessation, sodium <2 g/day, weight management, exercise
  • Monitor eGFR, ACR and potassium at 3-6 monthly intervals
  • Refer to nephrology for rapidly declining eGFR, ACR >=70 mg/mmol, or diagnostic uncertainty

Drugs & doses

Ramipril 2.5-10 mg PO daily (titrate to max tolerated)
Losartan 50-100 mg PO daily OR candesartan 8-32 mg PO daily
Dapagliflozin 10 mg PO once daily
Empagliflozin 10 mg PO once daily
Finerenone 10-20 mg PO once daily (if eGFR adequate and K+ <=4.8 mmol/L at start)
Atorvastatin 20 mg PO once daily (cardiovascular risk reduction)

Disposition

Primary care/CKD clinic for most; nephrology referral for rapid decline, heavy proteinuria, or uncertain diagnosis. Educate on sick-day medication rules.

Complications & pitfalls

  • Hyperkalaemia from RAAS blockade (+/- finerenone)
  • Functional AKI if hypovolaemic or on NSAIDs
  • Euglycaemic diabetic ketoacidosis (SGLT2)
  • Volume depletion/hypotension
  • Genital mycotic infections (SGLT2)
  • Progression to end-stage kidney disease despite therapy

Exam pearls

  • A small stable eGFR dip after RAAS or SGLT2 start is expected and protective — do not stop
  • SGLT2 inhibitors now benefit non-diabetic proteinuric CKD too
  • Do not combine ACE inhibitor with ARB (harm without benefit)
  • Give explicit SGLT2 sick-day rules to prevent euglycaemic DKA
  • Hold RAAS blockade during significant intercurrent illness with volume depletion

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.